June 09, 2022
The radiotherapy schedules used in the ATLAS trial reflect recent evidence and guideline changes for its usage in patients with high-risk localized or locally advanced prostate cancer.
June 06, 2022
The results, however, showed that remaining on mobocertinib may be warranted for patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer that has progressed after mobocertinib treatment.
June 03, 2022
The combination of ibrutinib plus the chemotherapy bendamustine and rituximab immunotherapy elicited the highest PFS rate ever reported for this patient population, according to an expert.
May 26, 2022
A Black patient with metastatic breast cancer explained that the results of the survey show that more work must be done by all stakeholders to increase the participation in clinical trials to accurately assess treatments in diversified populations.
February 19, 2022
New findings indicate that treatment with cabozantinib following failure of immunotherapy proved to be safe and feasible in metastatic renal cell carcinoma.
January 22, 2022
A safe and tolerable treatment option of transarterial chemoembolization combined with lenvatinib plus sintilimab was given to patients with hepatocellular carcinoma.
December 13, 2021
Patients with previously untreated chronic lymphocytic leukemia derived a better progression-free survival benefit from treatment with ibrutinib and rituximab vs fludarabine, cyclophosphamide, and rituximab.
December 11, 2021
Patients with chronic lymphocytic leukemia who were treated with ibrutinib and venetoclax in the first line continued to demonstrate deep, durable responses with new data showing further benefit to continuous ibrutinib therapy after 2 years.
September 25, 2021
Yoga not only yields improvements in physical, mental, and sexual wellbeing, but it may also result in reduced inflammation and antitumor responses in men with prostate cancer.
September 19, 2021
Durable objective responses coupled with an acceptable safety profile were reported for sabizabulin in patients with metastatic castration-resistant prostate cancer at 2021 ESMO.